Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

A Study of Anti-CD19 CAR T-cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis Pending

2024-511168-10-00 Primary or Secondary Progressive Multiple Sclerosis 4
STARS (Secukinumab in TAkayasu ARteritiS) Pending

2024-516215-24-00 TAkayasu ARteritiS 4
Hydroxychloroquine in progressive MS Pending

2025-522573-11-00 Multiple Sclerosis 4
A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have compl… Pending

2024-519638-22-00 IgA nephropathy 5
Omalizumab's dose reduction or increase in the frequency of administration in patients who suffer from allergic severe asthma Pending

2025-520782-48-00 Asthma 6
SCARR : « Allogenic Umbilical Cord Mesenchymal Stromal Cells for the treatment of chronic renal (cABMR) graft rejection » Pending

2023-506598-36-00 Adult Patients kidney transplant recipients who have de 10
Allogeneic adipose tissue-derived Mesenchymal stromal cells for the treatment of chronic-active antibody mediated rejection in Kidney transp… Pending

2024-510723-18-00 Chronic active antibody mediated rejection 7
Study to Assess K1-70 in Participants with Active Thyroid Eye Disease Recruiting

2024-519292-26-00 Graves’ disease and active thyroid eye disease 4 2026-05-28
Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
150 mg CIT-013 phase 1 trial Recruiting

2026-526153-34-00 Immune mediated inflammatory diseases 3 2026-05-26
A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting

2025-524001-33-00 Graves’ Disease 4 2026-05-22
A Study of KT-621 Administered Orally to Adult Participants with Moderate to Severe Eosinophilic Asthma Recruiting

2025-523180-38-00 Uncontrolled Moderate to Severe Eosinophilic Asthma 4 2026-05-21
A Study of JNJ-95597528 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis Recruiting

2025-523464-20-00 Moderate to Severe Atopic Dermatitis 4 2026-05-20
Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Par… Recruiting

2025-520988-41-00 Immunoglobulin G4 related Disease (IgG4-RD) 4 2026-05-15
A Phase II Open-Label Pilot Trial Assessing the Safety of Anifrolumab in Adult Patients with Primary Antiphospholipid Syndrome (APS). … Recruiting

2025-520918-64-00 Primary Antiphospholipid Syndrome (APS) 4 2026-04-24
A study to assess the effects of zigakibart on IgA nephropathy. Recruiting

2024-519699-24-00 IgA nephropathy 4 2026-04-23
Study to Evaluate the Efficacy and Safety of Deucrictibant for Prophylactic and On-demand Treatment of Angioedema Attacks in Adults with Acq… Recruiting

2025-522051-26-00 Acquired Angioedema due to C1 Inhibitor Deficiency 5 2026-04-23
Open-label extension study with filgotinib in children with juvenile idiopathic arthritis. Recruiting

2025-523239-21-00 Juvenile idiopathic arthritis 5 2026-04-13
A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults Recruiting

2025-522782-30-00 CCI 3 2026-04-07
A study to investigate the efficacy and safety of frexalimab versus tacrolimus in adults undergoing kidney transplantation Recruiting

2025-521521-33-00 Kidney transplant rejection 10 2026-04-02
Study to evaluate the effectiveness, safety, and quality of life of Bilaxten, an allergy medication, in children Recruiting

2024-519550-36-00 Allergic rhinoconjunctivitis 6 2026-03-30
MP: ADAPT Forward - Master protocol of a platform study to evaluate the safety and efficacy of multiple regimens in participants with Myasth… Recruiting

2025-522492-28-00 AChR-Ab Seropositive Generalized Myasthenia Gravis, Mya 4 2026-03-13
A Long-Term Follow-up Study for Subjects Previously Treated with A Century Therapeutics Cellular Therapy Product Recruiting

2024-520222-11-00 Hematological or solid tumor malignancies or autoimmune 3 2026-03-03
A study to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of surovatamig in adult participants with rheumatoid art… Recruiting

2025-522273-10-00 Systemic Lupus Erythematosus 3 2026-02-24